No clinical evidence supports their effectiveness for weight loss
When you take semaglutide or tirzepatide, these compounds bind directly to GLP-1 receptors located throughout your brain, gut, and pancreas
These effects result primarily from the medication's action on GLP-1 receptors throughout the gastrointestinal tract, which influence gut motility and digestive processes
Tirzepatide, marketed as Zepbound for weight management, has shown higher average weight loss than semaglutide in many trial comparisons
[3] When the body loses too much fluid, the kidneys may not get enough blood flow, which can trigger acute kidney injury (AKI)
[11] Any future GLP-1 patch would require robust clinical trial evidence demonstrating efficacy, safety, and pharmacokinetic profiles comparable to existing injectable formulations before regulatory approval could be granted